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Introduction
!
Dual antiplatelet therapy (DAPT) with aspirin and
a P2Y12-inhibitor (clopidogrel, ticagrelor, or pra-
sugrel) is recommended for up to 12 months fol-
lowing percutaneous coronary intervention (PCI)
with coronary drug-eluting stent (DES) implanta-
tion [1,2]. Although DAPT reduces the risk of ad-
verse cardiac events, it increases the risk of bleed-
ing, particularly in relation to surgical procedures
[3]. As a consequence, the need for surgery or in-
vasive procedures is a common reason for DAPT
interruption [4]. Surgery requiring interruption
of DAPT may trigger adverse cardiac outcomes in
patients with recent DES implantation [5].
The risk of adverse cardiac events and bleeding
complications differs depending on the type of
surgery [6]. Gastroscopy is associated with an
upper gastrointestinal bleeding risk <1% [7] and
guidelines recommend continuing DAPT
throughout gastroscopy with or without biopsy
[7]. However, adherence to guidelines is inconsis-
tent and DAPT is sometimes interrupted for this
minor invasive procedure [8], possibly because
personal experience with bleeding complications
may outweigh the perceived benefits of guideline
recommendations [8].
To the best of our knowledge, no study has hither-
to examined the association between DAPT strat-
egy for PCI patients in relation to gastroscopy and
the corresponding clinical outcomes. Subsequent-
ly, the aim of the present studywas to quantify (1)
the rate of gastroscopy within 12 months after
PCI, (2) the rate of adverse cardiac events and gas-
troscopy-related bleeding within 30 days of gas-
troscopy, and (3) the association between antipla-
telet therapy and these events.
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Background and study aims: Dual antiplatelet
therapy (DAPT) is recommended following percu-
taneous coronary intervention (PCI) with drug-
eluting stent (DES). DAPT is a risk factor for gas-
trointestinal bleeding. We aimed to quantify (1)
the rate of gastroscopy within 12 months after
PCI, (2) the rate of adverse cardiac events and gas-
troscopy-related bleeding complications within
30 days of gastroscopy, and (3) the association be-
tween antiplatelet therapy and these events.
Patients and methods: Patients receiving gastro-
scopy within 12 months of PCI were identified
and two nested case-control analyses were per-
formed within the PCI cohort by linking Danish
medical registries. Cases were patients with ad-
verse cardiac events (cardiac death, myocardial
infarction, or stent thrombosis) or hemostatic in-
tervention. In both studies, controls were patients
with gastroscopy including biopsy without ad-
verse cardiac events and hemostatic intervention,
respectively. Medical records were reviewed to
obtain information on exposure to DAPT.
Results: We identified 22 654 PCI patients of
whom 1497 patients (6.6%) underwent gastro-
scopy. Twenty-two patients (1.5%) suffered an ad-
verse cardiac event, 93 patients (6.2%) received
hemostatic intervention during or within 30
days of the index gastroscopy. Interrupting DAPT
was associatedwith a 3.46 times higher risk of ad-
verse cardiac events (95%CI 0.49–24.7). Disconti-
nuation of one antiplatelet agent did not increase
the risk (OR 0.65, 95%CI 0.17–2.47). No hemo-
static interventions were caused by endoscopic
complications.
Conclusion: Gastroscopy can be safely performed
in PCI patients treated with DES and single anti-
platelet therapy while interruption of DAPT may
be associated with an increased risk of adverse
cardiac events.
Methods
!
The study was approved by The Danish Data Protection Agency
(Ref: J.no.2012-41-0164). The Danish Health and Medicines Au-
thority approved medical record reviews (Ref: 3-3013-284/1).
Registry studies do not require ethical approval in Denmark.
Study setting and participants
Patients receiving gastroscopy within 12 months of PCI were
identified through Danish medical registries. We conducted two
nested case-control analyses within this cohort by linking Danish
medical registries. The nested case-control design allowed us to
retrieve data from the patients’medical records and to report ac-
curate information with regard to the exact timing of DAPT in re-
lation to gastroscopy with the same statistical precision but
without having to review all medical records of PCI patients
with subsequent gastroscopy.
The Danish Civil Registration System enabled us to collect infor-
mation, linked at the individual level, from national and regional
administrative and medical registries [9].
The Western Denmark Heart Registry (WDHR) collects patient
and procedure information on all coronary interventions per-
formed at the three coronary intervention centers in Western
Denmark (Odense University Hospital, Aarhus University Hospi-
tal, and Aalborg University Hospital). These centers cover a pop-
ulation of approximately threemillion inhabitants corresponding
to 55% of the Danish population [10]. Our study population con-
sisted of patients registered in the WDHR whowere treated with
one or more DES between July 2005 and December 2011 (n=22
654). For each patient, the index PCI procedure was defined as
the last PCI procedure performed during the study period.We ex-
cluded patients treated medically, with balloon angioplasty, or
with bare metal stents only, since guidelines do not always stipu-
late 12 months of DAPT treatment for these indications. For each
patient, the first gastroscopy after the index PCI was included.
The Danish National Patient Register (DNPR) contains data on all
hospital contacts since 1995, including dates of hospitalization,
outpatients and discharge diagnosis/procedures coded according
to the 10th revision of the International Classification of Diseases
(ICD-10) [11]. We linked WDHR and DNPR data to identify pa-
tients who underwent gastroscopy with or without biopsy (see
Appendix) within 12 months after PCI.
Data were collected from three university hospitals and 18 com-
munity hospitals to ensure a broad description of DAPT strategies
and complications.
Adverse cardiac events were defined as cardiac death, myocardial
infarction, or definite stent thrombosis within 30 days following
gastroscopy. Death was determined by using the Civil Registra-
tion System while information on cause of death (cardiac or
non-cardiac) was retrieved from the Danish Registry of Causes
of Death [12]. Cardiac death was defined as an evident cardiac
death or death from unknown causes. Myocardial infarction was
identified in the DNPR and defined as an acute admission plus an
ICD-10 discharge code of I21 [11]. Information on definite stent
thrombosis was obtained from the WDHR and defined according
to the Academic Research Consortium definition [13], and con-
firmed by review of medical records as described elsewhere
[14–16].
For the nested case-control analysis addressing adverse cardiac
events following gastroscopy, cases were patients experiencing
adverse cardiac events within 30 days following gastroscopy. For
each case, we identified four control patients who had a gastro-
scopy within 12 months after PCI, but experienced no adverse
cardiac events. The controls werematched by age (±5 years), gen-
der, and anticoagulant therapy with warfarin or phenprocou-
mon. Information on use of these drugs was retrieved from the
DNPR, which has collected individual-level data on all prescrip-
tion drugs sold in Danish pharmacies since 1994.The drugs are
recorded with Anatomic Therapeutic Codes (ATC) [17].
Gastroscopy-related bleeding complications were defined as he-
mostatic interventions (adrenalin injection or electrocoagula-
tion; ICD-10 codes are stated in the Appendix). Hemostatic inter-
ventions served as a surrogate marker for gastroscopy-related
bleeding complications, since the DNPR contains specific codes
for hemostatic intervention and since gastroscopy-related bleed-
ing complications in most instances will lead to hemostatic inter-
vention.
For the nested case-control study addressing gastroscopy-related
bleeding events, cases were patients receiving hemostatic inter-
vention during or within 30 days following the index gastrosco-
py. For each case, we identified two controls with gastroscopy
with biopsy, but without hemostatic intervention, to ensure a
comparative risk of bleeding. The controls were matched by age
(±10 years), gender, and anticoagulant therapy (using ATC codes
for warfarin and phenprocoumon). Compared to the first case-
control study, matching criteria (age) and number of controls
were altered to allow for sufficient matching.
One investigator (GE) systematically reviewed the medical re-
cords of the selected cases and controls in the two nested case-
control studies. We recorded treatment status (on or off treat-
ment) for aspirin and P2Y12-inhibitors during the period 30 days
before and 30 days after gastroscopy.
In the nested case-control analyses, patients were categorized as
receiving periprocedural antiplatelet treatment when treatment
was administered within 3 days before the gastroscopy. DAPT
was defined as treatment with both aspirin and a P2Y12-inhibitor.
Single antiplatelet therapy (SAPT) was defined as treatment with
only one antiplatelet agent (aspirin or P2Y12-inhibitor), and inter-
rupting DAPT was defined as no antiplatelet treatment within 3
days before gastroscopy. Periprocedural treatment was regis-
tered for aspirin and P2Y12-inhibitors separately. Gastroscopies
were defined as acutewhen performedwithin 3 days of acute ad-
mission.
Baseline data and covariates
For each patient, we computed comorbidity scores using the
Charlson Comorbidity Index. This index covers 19 major disease
categories, including diabetes mellitus, heart failure, cerebrovas-
cular diseases, and cancer. This score is a weighted summary of
previous diagnoses, with weights based on the 1-year mortality
associated with each disease in the original Charlson dataset.
The Charlson Comorbidity Index has recently been validated in a
cohort of acute coronary syndrome patients [18]. In this study,
we used an adjusted Charlson Comorbidity Index score that did
not include diabetes and previous myocardial infarction since
these two conditions were considered separately.
Data on prescription medication not obtained from medical re-
cords were obtained from the DNPR (see Appendix for ATC codes)
[17]. Patients were considered to be on treatment when a pre-
scriptionwas redeemed within 100 days before gastroscopy. Fur-
ther demographic and clinical data were collected from the
WDHR.
Since the risk of adverse cardiac events associated with DAPT dis-
continuation declines with time after PCI [19], we also calculated
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time from index PCI to gastroscopy. We defined and categorized
gastroscopy as acute when performed within 3 days after acute
admission.
Statistics
Baseline variables were presented as counts (%) apart from age,
which was stated as median (interquartile range; IQR (Q1–Q3)).
In the nested case-control studies, we used conditional logistic
regression to compute odds ratios for adverse cardiac events and
gastroscopy-related bleeding complications among the different
periprocedural antiplatelet strategies. All statistical analyses
were performed using Stata 13 (Statacorp, College Station, TX,
United States).
Results
!
In a cohort of 22654 patients treated with coronary DES implan-
tation, we identified 1497 patients (6.6%) who underwent gas-
troscopy within 12months of PCI; of these, 1046 had gastroscopy
with biopsy. Within 30 days after gastroscopy, 45 (3%) patients
died. Thirteen of these suffered a cardiac death while nine had a
myocardial infarction, two of which were caused by stent throm-
bosis, yielding a total of 22 (1.5%) adverse cardiac events within
the first 30 days following gastroscopy. Ninety-three patients
(6.2%) received hemostatic intervention during gastroscopy
(●" Fig.1).
For the nested case-control studies, we collected information
from the medical records of 109 patients in the adverse cardiac
events study and 279 patients in the hemostatic intervention
study. A single medical record (a control from the adverse cardiac
events nested case-control study) was not obtainable andwas re-
corded as missing. The gastroscopies were performed with a me-
dian time after PCI of 145 days (IQR, 60–249) (●" Fig.2). P2Y12-in-
hibitors were clopidogrel for cases and controls, apart from four
controls in the gastroscopy related bleeding group on ticagrelor.
Adverse cardiac events
In the nested case-control study focusing on adverse cardiac
events, data were obtained for 22 cases and 87 gastroscopy con-
trols. The median time from PCI to gastroscopy was 132 days
(IQR, 33–248 days) for cases and 125 days (IQR, 48–224 days)
for controls. Demographic and clinical characteristics are provid-
ed in●" Table1.
In this nested case-control cohort including 109 patients, 91% re-
ceived aspirin and 97% received a P2Y12-inhibitor before gastro-
scopy. Treatment with these drugs was interrupted >3 days be-
fore gastroscopy for 24% of the patients taking aspirin and for
23% of patients taking P2Y12-inhibitors. Aspirin or a P2Y12-inhib-
itor treatment was resumed in 9% and 14% of patients, respec-
tively, within 7 days following gastroscopy.
PCI with DES 2005–2012, n = 22 654
All-cause death before 
gastroscopy, n = 977
No gastroscopy 
within 12 months, n = 20 180
Non-cardiac death within 30 days 
after gastroscopy, n = 32
Missing 
medical 
records, n = 1
Gastroscopy within 12 months of PCI, n = 1497
Adverse cardiac events within 
30 days after gastroscopy, n = 22
No adverse cardiac events within 
30 days after gastroscopy, n = 1443
DES PCI patients with gastroscopy 
and adverse cardiac events (cases), 
n = 22
Matched DES PCI patients with 
gastroscopy without adverse
cardiac events (controls), n = 87
PCI with DES 2005–2012, n = 22 654
All-cause death before 
gastroscopy, n = 977
No gastroscopy within 12 
months, n = 20 180
Non-cardiac death within 30 days 
after gastroscopy, n = 32
Gastroscopy within 12 months of PCI, n = 1497
Hemostatic intervention within 30 
days after gastroscopy, n = 93
No hemostatic intervention within 
30 days after gastroscopy, n = 1372
DES PCI patients with gastroscopy 
and hemostatic intervention 
(cases), n = 93ba
Matched DES PCI patients with 
gastroscopy without hemostatic 
intervention (controls), n = 186
Fig.1 Flowchart of patient selection for the nested case-control studies. a Adverse cardiac events nested case-control study. b Hemostatic interventions
during gastroscopy nested case-control study. DES, drug-eluting stent; PCI, percutaneous coronary intervention.
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Fig.2 Time from DES implantation to gastroscopy. The incidence (per-
centage) of gastroscopy in PCI patients, categorized by time from PCI to
gastroscopy.
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Among patients with an adverse cardiac event, 9% did not receive
any antithrombotic treatment at the time of gastroscopy and 77%
received DAPT (●" Table2). The risk of cardiac events was 3.46
times higher among patients not receiving antiplatelet therapy
compared to those receiving DAPT (95% confidence interval (CI)
0.49–24.71). Single antiplatelet therapy (SAPT) was not associat-
ed with an increased risk compared to DAPT therapy (odds ratio
(OR) 0.65, 95%CI 0.17–2.47).
Gastroscopy-related bleeding
In the nested case-control study of gastroscopy-related bleeding,
we obtained data from 93 cases receiving a hemostatic interven-
tion and 186 controls without such intervention. The median
time from PCI to gastroscopy was 114 days (IQR, 52–224 days)
for cases and 166 days (IQR, 70–267 days) for controls. Demo-
graphic and clinical characteristics are presented in ●" Table1
and periprocedural treatment in●" Table2.
In this nested case-control cohort of 279 patients, 92% received
aspirin and 94% a P2Y12-inhibitor before gastroscopy. Treatment
with these drugs was interrupted >3 days before gastroscopy for
37% of the patients taking aspirin and for 33% of the patients tak-
ing P2Y12-inhibitors. Aspirin or P2Y12-inhibitor treatment was re-
sumed in 15% and 20% of patients, respectively, within 7 days fol-
lowing gastroscopy.
A total of 1046 patients had gastroscopy with biopsy. Using he-
mostatic intervention as a surrogate marker for bleeding compli-
cations, none of these 1046 patients had complications in rela-
tion to the biopsies.
Table 1 Demographic and clinical data for patients in the two nested case-control studies.
Adverse cardiac event study Gastroscopy-related bleeding event study
Cases, n =22 Controls, n =87 Cases, n =93 Controls, n =186
Demographics
Age, median (IQR), years 73 (66–79) 73 (66–79) 72 (65–79) 71 (64–79)
Sex, male, no. (%) 12 (54.5) 48 (54.5) 71 (76.0) 142(76.0)
Smoking, no. (%) 5 (23.8) 16 (18.3) 25 (26.8) 43 (23.1)
Drug exposure, no (%)
Proton-pump inhibitors 9 (40.9) 38 (45.8) 32 (36.0) 96 (52.75)
Statins 10 (45.5) 57 (68.7) 69 (77.5) 138 (75.8)
Vitamin K-antagonists 3 (13.6) 14 (16.9) 8 (9.0) 17 (9.3)
NSAIDs 1 (4.5) 9 (10.9) 12 (13.5) 6 (3.3)
Cox 2-inhibitors 3 (13.6) 4 (4.8) 11 (12.4) 12 (6.6)
Oral glucocorticoids 2 (9.0) 12 (14.5) 11 (12.4) 15 (8.2)
Calcium antagonists 6 (27.3) 34 (41.0) 21 (23.6) 52 (28.6)
Beta blockers 12 (54.5) 51 (61.5) 60 (67.4) 136 (74.7)
SSRIs 2 (9.0) 11 (13.2) 12 (13.5) 30 (16.5)
Nitrates 4 (18.2) 14 (16.9) 18 (20.2) 33 (18.1)
Comorbidities
Hypertension, no. (%) 11 (61.1) 49 (63.6) 47 (58.8) 105 (66.5)
Hypercholesterolemia, no. (%) 7 (38.9) 46 (60.5) 46 (57.5) 105 (66.5)
Previous MI, no. (%) 3 (16.7) 21 (26.9) 20 (25.6) 33 (20.9)
Diabetes, no. (%) 2 (9.0) 15 (17.2) 15 (16.3) 28 (15.2)
Charlson Comorbidity Index,1 mean 0.9 0.8 1.1 0.8
Lesion and procedural characteristics
Stent > 1, % 55 36 33 32
Stent length > 20mm, % 62.1 45.2 48.6 49.3
PCI indication ACS, no. (%) 13 (59) 40 (45) 59 (63) 94 (51)
PCI indication SAP, no. (%) 8 (36) 44 (50) 31 (33) 87 (47)
Indication2 UGIH, no. (%) 17 (77) 31 (35) 93 (100) 48 (26)
Indication2 dyspepsia, no. (%) 5 (23) 31 (35) 0 25 (13)
Indication2 anemia, no. (%) 0 24 (27) 0 111 (60)
IQR, interquartile range; NSAIDs, nonsteroidal anti-inflammatory drugs; Cox, cyclooxygenase; SSRIs, selective serotonin re-uptake inhibitors; MI, myocardial infarction; PCI,
percutaneous coronary intervention; ACS, acute coronary syndrome; SAP, stable angina pectoris; UGIH, upper gastrointestinal hemorrhage.
1 Modified score, see Methods section.
2 Indication for gastroscopy.
Table 2 Periprocedural antiplatelet treatment in patients included in the nested case-control studies.
Group DAPT Only a P2Y12-inhibi-
tor
Only aspirin No treatment
Adverse cardiac event study
Cases (N=22), no. (%) 17 (77) 1 (5) 2 (9) 2 (9)
Controls (N = 87), no. (%) 67 (77) 12 (14) 6 (7) 2 (2)
Gastroscopy-related bleeding event study
Cases (N=93), no. (%) 79 (85) 5 (5.5) 5 (5.5) 4 (4)
Controls (N = 186), no. (%) 138 (74) 18 (10) 19 (10) 11 (6)
DAPT, dual antiplatelet therapy.
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All 93 cases who received a hemostatic intervention had suffered
spontaneous bleeding before gastroscopy. Of these, 91 hemostat-
ic interventions were performed during index gastroscopy and
two at a new gastroscopy within 30 days. Thus, none of the
hemostatic interventions were caused by gastroscopy-related
bleeding complications due to biopsy. Gastroscopy was per-
formed acutely in 84 cases (90%) while the remaining cases had
gastroscopy performed electively. In the control group, 129 gas-
troscopies (69%) were performed electively.
None of the controls had a hemostatic intervention within 30
days after gastroscopy. Among cases, 85% received DAPT, 11% re-
ceived single antiplatelet therapy (SAPT) and 4% received no
periprocedural antiplatelet treatment. After initial gastroscopy,
13 cases and two controls had re-gastroscopy on suspicion of ac-
tive bleeding during admission; however, no active bleeding was
found.
Discussion
!
In this population-based cohort, gastroscopywas required in 6.6%
of patients within the first year after PCI with DES.Of these, 1.5%
suffered an adverse cardiac event and 6.2% had a hemostatic in-
tervention within 30 days following gastroscopy. Interrupting
DAPT seemed to be associated with an increased risk of cardiac
events in our cohort. Importantly, continuation of a single anti-
platelet agent in relation to gastroscopy had the same protective
effect against adverse cardiac events as DAPT. Review of themed-
ical journals revealed that none of the cases in need of a hemo-
static intervention had the intervention due to complications
related to gastroscopy regardless of their antiplatelet therapy,
and none of the controls required hemostatic intervention after
biopsy, therefore SAPTor DAPTshould thus not be a contraindica-
tion for hemostatic intervention or biopsy during gastroscopy.
Adverse cardiac events related to gastroscopy
The adverse cardiac event rate of 1.5% within 30 days following
gastroscopy in our study population should be considered in the
light of a reported event rate of 5% within 9 months among pa-
tients treated with DES [16]. There are limited reports with re-
gard to adverse cardiac events following gastroscopy [20–23]
and we can only extrapolate from settings not involving proce-
dures following PCI. We speculate that the explanation for the
higher rate of adverse cardiac events observed here, apart from
pre-existing cardiovascular disease, may be hemodynamic in-
stability or a pro-thrombotic state related to bleeding events
due to hypovolemia. In our cohort, 43% of gastroscopies were
performed due to clinically manifest, or suspicion of, upper gas-
trointestinal bleeding. Also, the indication for gastroscopy, i. e.
confirmed or suspected upper gastrointestinal bleeding, may be
associated with interruption of antiplatelet treatment. We found
a high compliance rate of 77% for DAPT during gastroscopy for
both cases and controls, resulting in very little information con-
trast rendering the confidence interval broad and the odds ratio
without a traditional statistical significance of 5%. However, a re-
lative risk of 3.46 for an adverse cardiac event if the patients do
not receive any DAPT during gastroscopy is not negligible.
The Standards of Practice Committee of the American Society for
Gastrointestinal Endoscopy (ASGE) recommends continuation of
DAPT throughout gastroscopy in these patients [7]. A recently re-
ported survey among endoscopists noted that only 30% of re-
sponding endoscopists adhered to the ASGE guidelines on anti-
platelet therapy in relation to endoscopic procedures. Among re-
spondents, 26% withheld all antiplatelet therapy before engaging
in any patient procedure, possible exposing the patients to an in-
creased ischemic risk [8]. DAPT interruption in patients with DES
is a strong predictor of ischemic events [5,24]. However, while
discontinuation of both aspirin and clopidogrel, one of the avail-
able P2Y12-inhibitors, was associated with stent thrombosis, con-
tinuation of aspirin and discontinuation of clopidogrel was not
[24,25]. Accordingly, we found that reduction in periprocedural
DAPT to a single antiplatelet agent, but with no difference be-
tween aspirin and clopidogrel, yielded the same protection
against cardiac events as DAPT. Consequently, reduction in DAPT
to aspirin or clopidogrel alone seems a safe choice in patients on
DAPTwho await gastroscopy on the suspicion of upper gastroin-
testinal bleeding.
Risk of gastroscopy-related bleeding in patients
with DES implantation
Most importantly, we found that neither cases nor controls in
the two nested case-control studies had bleeding episodes as a
complication to gastroscopy with or without biopsy despite the
high rate of periprocedural DAPT. These data strongly suggest
that both elective and acute gastroscopy can be performed safely
in patients receiving DAPT, although short intermittent reduc-
tion to a single antiplatelet agent also seems safe with regard to
adverse cardiac events. Aspirin is known to injure the gastric
mucosa while clopidogrel does not [26]. In the randomized,
blinded CAPRIE study of clopidogrel versus aspirin in patients
at risk of ischemic events, gastrointestinal bleeding was signifi-
cantly less frequent in patients treated with clopidogrel 75mg
daily vs. aspirin 325mg daily (0.52% vs. 0.72%) [27] while a pro-
spective, randomized study involving 630 biopsies in healthy
volunteers found no clinically important bleeding regardless of
treatment with aspirin or clopidogrel [28]. The added effect of
clopidogrel and aspirin further increases the relative risk of
bleeding up to 50%. These studies thus indicate that aspirin and
clopidogrel have very similar risks of gastrointestinal bleeding
when used separately while the combined use increases the
risk of bleeding. In this setting, it is important to note that our
data support the recommendations that DAPT should not be
routinely interrupted before gastroscopy and also that hemo-
static intervention or biopsy can be performed safely in patients
receiving aspirin and/or a P2Y12-inhibitor within 3 days before
gastroscopy.
Collective strategy for patients undergoing gastroscopy
after PCI
The optimal treatment strategy for a patient with gastrointesti-
nal bleeding, who has recently undergone a PCI procedure, is
complex with competing risks of rebleeding and adverse cardiac
events. The recently updated European Joint Task Force Guide-
lines on Non-cardiac Surgery [6] recommends continued DAPT
at the time of gastroscopy, but acknowledges the absence of ran-
domized clinical trial data supporting this and that clinical cir-
cumstances with bleeding complications may necessitate sus-
pension of either one or both antiplatelet agents [6].
In our study, we included both acute and elective gastroscopies to
cover the diversity among patients needing a gastroscopy. This
also means that, in some patients, there was no time to reduce
DAPT. Despite this, no complications were observed which were
directly related to hemostatic intervention or biopsy, which falls
in line with the guidelines. Nevertheless, the challenge is patients
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who are under suspicion for upper gastrointestinal bleeding
while on DAPT, leading to gastroscopy.
In our study, the majority of cases had acute gastroscopy and
hence there was no opportunity to plan a treatment strategy.
Even so, no cases had further bleeding leading to hemostatic in-
tervention after the initial gastroscopy. From the potential de-
creased bleeding risk by reduction from DAPT to a single antipla-
telet agent, and based on our finding of a low risk of adverse car-
diac events in patients treatedwith a single antiplatelet agent, we
advocate a single antiplatelet strategy for a shorter period in pa-
tients with a suspected acute bleeding episode. The clinical situa-
tion, the comorbidities, and the risk stratification by gastroscopy,
will allow the treating physician to judge if, and when, DAPT can
be re-initiated. Among elective patients, our data indicate that it
is safe to either continue DAPTor reduce DAPT to a single antipla-
telet agent 3 days before gastroscopy. The combined evidence
from several studies including the current study indicate that it
is safe to reduce DAPT to SAPT, whereas stopping both antiplate-
let agents is associated with an increased risk of adverse cardiac
events [29–31]. In Denmark, the guidelines only stipulate proton
pump inhibitor (PPI) treatment for patients on DAPT, if the pa-
tients have risk factors for ulcer present at the time of PCI. The
proportions of patients on PPI treatment were relatively low.
Since 6.6% of DES-treated patients undergo gastroscopy within
12 months and since PPIs reduce the risk of upper gastrointesti-
nal bleeding [32], one may consider making PPI treatment the
standard of care in patients receiving DAPT.
Strengths and limitations
The strength of our study is its combined evaluation of both 30-
day risk of adverse cardiac events and 30-day bleeding risk fol-
lowing gastroscopy. We were able to identify the patients who
suffered adverse cardiac events using Danish registries with
documented validity [10]. In addition, individual patient medical
records were thoroughly examined to extract specific informa-
tion about procedures, outcomes, and medical therapy. Never-
theless, separating adverse cardiac events from bleeding events
is not straightforward since an important interaction between
the two types of events is likely as major bleeding may lead to
myocardial infarction. Major bleeding, compared to minor bleed-
ing, is associated with a higher risk of interrupting both aspirin
and P2Y12-inhibitor treatment and of pro-thrombotic states,
blood transfusions, and hemodynamic instability, all of which
may affect the risk of adverse cardiac events. Our risk estimates
were imprecisewith broad confidence intervals since compliance
to DAPTwas relatively high and event rates relatively low despite
evaluating all 1497 gastroscopies in a cohort of 22654 PCI pa-
tients. Our study was restricted to patients treated with DES,
which represents more than 90% of all patients in the WDHR
during the study period. DAPT is usually discontinued 3–5 days
before a surgical procedure. During this interruption, patients
may suffer an adverse cardiac event before the gastroscopy with
consequent cancellation of the procedure. Such incidents could
not be detected with our study design. Evaluating the patient’s
record gave us information on indication for gastroscopy. In the
reoperation for bleeding study, the indication for cases was
more often upper gastrointestinal hemorrhage compared to con-
trols; however, we cannot rule out the possibility that this is due
to information bias as a patient in need of a hemostatic interven-
tion could more likely be classified as having upper gastrointesti-
nal hemorrhage as indication whereas the indication anemia
might be used if there is no active bleeding.
Conclusions
!
Gastroscopy is commonwithin the first year after stent implanta-
tion, and management of the PCI-related DAPT represents a clin-
ical challenge.We observed a relatively high risk of adverse cardi-
ac events and hemostatic interventions. A single antiplatelet
strategy may reduce the need for hemostatic intervention while,
in accordancewith previous studies, interruption of both antipla-
telet agents seems associated with adverse cardiac events. A sin-
gle antiplatelet strategy does thus seem recommendable in pa-
tients suspected of having upper gastrointestinal bleeding.
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Table 3 ICD 10 codes used.
ICD 10 code
Gastroscopy with or without biopsy KUJD02, KUJD05
Hemostatic interventions (adrenalin
injection or electrocoagulation)
KJDA32, KJDA 35, KJDH18,
and KJDH15
Table 4 ATC codes for redeemed prescription medications within 100 days
before surgery.
Medication ATC code
Vitamin K antagonists B01AA03, B01AA04
Statins C10AA01-2, C10AA04-5
Proton pump inhibitors A02BC01, A02BC02, A02BC03,
A02BC04, A02BC05
Calcium channel blockers C08CA01-3, C08CA05, C08CA08,
C08CA09, C08CA13, C08CX01,
C08DA, C08DB01
Cyclooxygenase-2 selective
inhibitors
M01AH, M01AB05, M01AB55,
M01AB08, M01AC06, M01AX01
Nonselective nonsteroidal
anti-inflammatory drugs
M01AB01, M01AC01, M01AE01,
M01AE51, M01AE02, M01AE03,
M01AE53, M01AE14, M01AG02
Systemic glucocorticoids H02AB
Beta blockers C07
Anti-depressives (SSRIs) N06AB04, N06AB10, N06AB03,
N06AB05, N06AB06
Nitrates C01DA02
Low molecular weight heparin
(LMWH)
B01AB05, B01AB10, B01AB04
SSRIs, selective serotonin re-uptake inhibitors
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